UCB has agreed to acquire Candid Therapeutics for up-to-$2.2 billion, in a deal designed to expand the buyer’s presence in ...

Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines Current Regenerative Medicine Advanced ...

UCB will pay up to $2.2bn for Candid Therapeutics, betting on cizutamig and the wider T-cell engager rush in autoimmune disease.

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

UCB, a global biopharmaceutical company, today announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology ...

New advancements in medical technology highlight AI’s potential to address racial disparities in heart disease diagnosis and ...

Allogene Therapeutics Inc. (NASDAQ:ALLO) is a clinical-stage biotechnology company dedicated to the development of ...

WuXi AppTec, a leading global contract research, development, and manufacturing organization (CRDMO) presented 13 scientific ...

Chimeric antigen receptor-T (CAR-T) cell therapy represents a major breakthrough in cancer immunotherapy, providing remarkable clinical benefits for ...

Researchers announced three major cancer advances, including a novel dual-action drug for pancreatic cancer, new insights into CAR T-cell therapy failures, and the FDA's real-time clinical trial ...

Syncromune is advancing SYNC-T Therapy SV-102 in the ongoing Phase 2 LEGION-100 study (NCT06533644), which is actively enrolling across multiple sites in the U.S. Please visit www.legion100trial.com ...

Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer ...